Peking University Sixth Hospital

Beijing 100191

1 studies enrolling now · 9 studies all time

What they study most

Alzheimer Disease, Alzheimers Disease, Anhedonia, Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant, Psychotic Disorders, Schizophrenia

Studies at this site

• A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease — Recruiting now
• A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) — Stopped early
• A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study — Stopped early
• A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive Medicine — Completed
• A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy — Completed
• Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-1) — Completed
• Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD) — Running, not enrolling
• This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year — Stopped early
• A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression — Completed